Abstract 1116
Background
The purpose of current study is to discriminate primary central nervous system lymphoma from metastatic brain tumors with 3D texture features.
Methods
A total number of 120 patients involved this study, 58 with PCNSL and 62 with MBTs. Texture features were retrieved from histogram matrix and GLCM matrix. Mann Whitney U tests were performed to detect if texture feature were significantly different between two type of tumors. Binary logistic regressions were conducted to detect if they could be taken as independent predictors, based on which integrated model was built. ROC curves of each parameter were generated to evaluate the ability in discrimination.
Results
Three texture features (histo-Kurtosis, GLCM-Contrast and GLCM-Dissimilarity from post contrast T1WI) were independent predictors in discrimination, whose AUC were 0.632, 0.742 and 0.706 respectively. The integrated model represented better diagnostic value than any single features. ROC curve suggested the AUC of model was 0.832, representing practical clinical value.
Conclusions
Texture analysis has potential in the differentiation between primary central nervous system lymphoma from metastatic brain tumors. Moreover, combination of single texture shows more promising and effective ability in discrimination.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xuelei Ma.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5189 - Association between serum HGF levels and neutrophil counts in small cell lung cancer and their impact on survival
Presenter: Laura Moliner
Session: Poster Display session 1
Resources:
Abstract
3539 - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC.
Presenter: Clelia Tiziana Storlazzi
Session: Poster Display session 1
Resources:
Abstract
3438 - High-biologically effective dose radiotherapy improve the survival of small cell lung cancer patients with brain metastases: a propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster Display session 1
Resources:
Abstract
3232 - Phase 1 open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract
3633 - Activity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer
Presenter: Carminia Maria Della Corte
Session: Poster Display session 1
Resources:
Abstract
3745 - Multi-level proteomics identifies FABP5 as a primary chemoresistance mediator in extensive-stage small cell lung cancer
Presenter: Yamei Chen
Session: Poster Display session 1
Resources:
Abstract
5049 - CLEPSIDRA trial: a pilot, biomarker-guided study to assess safety, tolerability, dose finding and efficacy of iadademstat in combination with platinum-etoposide in patients with relapsed, extensive-stage small cell lung cancer
Presenter: Alejandro Navarro Mendivil
Session: Poster Display session 1
Resources:
Abstract
5997 - Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer (SCLC): The PAVE study, a Hellenic Cooperative Oncology Group Study
Presenter: Helena Linardou
Session: Poster Display session 1
Resources:
Abstract
4502 - Tobacco use in lung cáncer (LC) patients (p) in Spain
Presenter: Enric Carcereny Costa
Session: Poster Display session 1
Resources:
Abstract
4369 - Biomarker testing of lung cancer in Spain
Presenter: Delvys Rodriguez Abreu
Session: Poster Display session 1
Resources:
Abstract